Electromed Inc
$ 37.61
1.16%
11 Jun - close price
- Market Cap 307,853,000 USD
- Current Price $ 37.61
- High / Low $ 38.03 / 36.11
- Stock P/E 31.78
- Book Value 5.94
- EPS 1.17
- Next Earning Report 2026-08-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.15 %
- ROE 0.22 %
- 52 Week High 40.00
- 52 Week Low 17.73
About
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in lung care for patients of all ages in the United States. and internationally. The company is headquartered in New Prague, Minnesota.
Analyst Target Price
$40.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-02-10 | 2025-11-12 | 2025-08-26 | 2025-05-13 | 2025-02-11 | 2024-11-12 | 2024-08-27 | 2024-05-07 | 2024-02-13 | 2023-11-07 | 2023-08-22 |
| Reported EPS | 0.3473 | 0.32 | 0.25 | 0.25 | 0.21 | 0.22 | 0.16 | 0.2 | 0.17 | 0.19 | 0.02 | 0.12 |
| Estimated EPS | 0.2375 | 0.26 | 0.21 | 0.22 | 0.2 | 0.18 | 0.03 | 0.14 | 0.13 | 0.1 | 0.1 | 0.13 |
| Surprise | 0.1098 | 0.06 | 0.04 | 0.03 | 0.01 | 0.04 | 0.13 | 0.06 | 0.04 | 0.09 | -0.08 | -0.01 |
| Surprise Percentage | 46.2316% | 23.0769% | 19.0476% | 13.6364% | 5% | 22.2222% | 433.3333% | 42.8571% | 30.7692% | 90% | -80% | -7.6923% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-25 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.32 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELMD
2026-06-09 21:10:33
Electromed, Inc.'s CEO and President, James L. Cunniff, reported selling 9,700 shares of common stock in multiple open-market transactions on June 8, 2026. Concurrently, he exercised employee stock options to acquire 9,700 shares at a lower strike price. Following these transactions, Cunniff directly holds 147,751 shares of Electromed common stock.
2026-06-09 00:08:58
Electromed's CFO, Bradley M. Nagel, sold shares worth approximately $428,936 on June 4, 2026, after the stock experienced a 77% gain over the past year. Concurrently, Nagel acquired 9,601 shares through employee stock options. This comes as Electromed reported strong Q3 fiscal year 2026 results, exceeding analyst expectations for both EPS and revenue.
2026-06-09 00:08:58
Electromed, Inc.'s CFO, Bradley M. Nagel, exercised stock options to acquire 9,601 shares and subsequently sold 11,801 common shares on June 4, 2026. The sales were executed in open-market transactions at weighted average prices of approximately $36.34 and $37.11 per share. Following these transactions, Nagel retains significant options expiring in 2033.
2026-06-08 17:08:58
This SEC filing for Electromed, Inc. (ELMD) is a Form 144, indicating a proposed sale of securities. The document details the filer information, issuer information, and the specifics of the securities to be sold, including the acquisition date and nature of the transaction. It also confirms that no securities were sold during the past three months by the person filing this notice.
2026-06-04 20:10:45
Electromed, Inc. (ELMD) filed a Form 144, indicating proposed sales of common stock. The filing details two entries: 2,200 shares from "Restricted Stock Vesting" dated June 30, 2024, and 9,601 shares from a "Stock Option Exercise" dated June 4, 2026, with Fidelity Brokerage Services LLC facilitating the transactions on NYSE American. This notice signifies potential future transactions, with actual sales dependent on Rule 144 conditions.
2026-05-29 16:02:00
Electromed, Inc. has reached a new 52-week high of $39.35, marking a 468.6% increase over the past year, significantly outperforming the S&P 500. The microcap company in the Pharmaceuticals & Biotechnology sector boasts a market capitalization of $197 million and demonstrates strong financial health with a P/E ratio of 22.00, return on equity of 20.11%, and a 52-week low of $17.73. These metrics indicate robust growth and stability for the company.
